Translational Research Methods in Diabetes, Obesity, and Nonalcoholic Fatty Liver Disease A Focus on Early Phase Clinical Drug Development /

• Συγγραφή απο Οργανισμό/Αρχή: SpringerLink (Online service)
• Άλλοι συγγραφείς: Krentz, Andrew J. (Επιμελητής έκδοσης, http://id.loc.gov/vocabulary/relators/edt), Weyer, Christian (Επιμελητής έκδοσης, http://id.loc.gov/vocabulary/relators/edt), Hompesch, Marcus (Επιμελητής έκδοσης, http://id.loc.gov/vocabulary/relators/edt)
• Μορφή: Ηλεκτρονική πηγή Ηλ. βιβλίο
• Γλώσσα: English
• Έκδοση: Cham : Springer International Publishing : Imprint: Springer, 2019.
• Έκδοση: 2nd ed. 2019.
• Θέματα: Diabetes.; Metabolic diseases.; Pharmacology.; Metabolic Diseases.; Pharmacology/Toxicology.

This book aims to aid the selection of the most appropriate methods for use in early phase (1 and 2) clinical studies of new drugs for diabetes, obesity, non-alcoholic fatty liver disease (NAFLD) and related cardiometabolic disorders. Clinical research methods to assess the pharmacokinetics and phar...

Πίνακας περιεχομένων:

• Part 1: Review of Clinical Investigative Methods
• Chapter 1: Quantifying Insulin Action in Humans
• Chapter 2: Assessment of Islet Alpha- and Beta-Cell Function
• Chapter 3: Pharmacokinetic and Pharmacodynamic Assessment of Novel and Biosimilar Insulins
• Chapter 4: Measurement of Energy Expenditure
• Chapter 5: QUANTIFYING APPETITE AND SATIETY
• Chapter 6: Non-invasive quantitative magnetic resonance imaging and spectroscopic biomarkers in nonalcoholic fatty liver disease and other cardiometabolic diseases associated with ectopic fat deposition
• Chapter 7: Structural and Functional Imaging of Muscle, Heart, Endocrine Pancreas and Kidneys in Cardiometabolic Drug Development
• Chapter 8: Positron emission tomography and computed tomography measurement of brown fat thermal activation: key tool for developing novel pharmacotherapeutics for obesity and diabetes
• Chapter 9: Isotopic Tracers for the Measurement of Metabolic Flux Rates
• Chapter 10: Role of Tissue Biopsy in Drug Development for NonAlcoholic Fatty Liver Disease and Other Metabolic Disorders
• Chapter 11: Utility of Invasive and Non-invasive Cardiovascular Research Methodologies in Drug Development for Diabetes, Obesity and NAFLD/NASH
• Chapter 12: Omics: Potential role in early phase drug development
• Part 2: Preclinical Drug Development and Transitioning to Clinical Studies
• Chapter 13: Peptide Drug Design for Diabetes & Related Metabolic Diseases
• Chapter 14: ANIMAL MODELS OF TYPE 2 DIABETES, OBESITY AND NONALCOHOLIC STEATOHEPATITIS - CLINICAL TRANSLATABILITY AND APPLICABILITY IN PRECLINICAL DRUG DEVELOPMENT
• Chapter 15: Drug Development for Diabetes Mellitus: Beyond Hemoglobin A1c
• Chapter 16: Emerging Circulating Biomarkers For The Diagnosis And Assessment Of Treatment Responses In Patients With Hepatic Fat Accumulation, Nash And Liver Fibrosis
• Chapter 17: Quantitative Approaches in Translational Cardiometabolic Research: An Overview
• Chapter 18: Transitioning from Preclinical to Clinical Drug Development
• Chapter 19: Regulatory Considerations for Early Study and Clinical Development of Drugs for Diabetes, Obesity, NonAlcoholic Steatohepatitis (NASH) and other Cardiometabolic Disorders
• Chapter 20: Early Phase Metabolic Research with Reference to Special Populations.